Fibrin Matrix Therapy Products in Oceanside, CA

CDC PLACES vs. JE: two files, not one brochure

Adult obesity in Oceanside is 26.1% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 10.4% of adults in Oceanside have diagnosed diabetes — 1.6 points below the U.S. 12% figure. California is outside CDC’s core Diabetes Belt list; use the PLACES city rate anyway. Hawk Medical is the distributor for fibrin matrix therapy, not a walk-in clinic.

Cash PRP and Medicare CTPs in the same hallway

• CDC PLACES (2023, crude) estimates 10.4% of adults in Oceanside have diagnosed diabetes — 1.6 points below the U.S. 12% figure. Adult obesity in Oceanside is 26.1% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. A CTP without offloading and serial measurements still fails JE review. Product is the last step, not the first.
• Orthopedic and wound-care buyers in California are often different people inside the same health system. A single Hawk Medical account can still require two utilization policies so 361 tissue and CTPs are not interchanged.
• California is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Payer geography for Oceanside, CA

JE reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Oceanside is 10.4% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic